Try a new search

Format these results:

Searched for:

in-biosketch:true

person:gudesm01

Total Results:

248


Baseline cognitive function of patients with relapsing remitting multiple sclerosis is associated with therapeutic response to Natalizumab [Meeting Abstract]

Golan, Daniel; Gudesblatt, Mark; Wissemann, Karl; Zarif, Myassar; Bumstead, Barbara; Fafard, Lori; Sullivan, Cynthia; Wilken, Jeffrey; Blitz-Shabbir, Karen; Buhse, Marijean; Doniger, Glen
ISI:000453090805089
ISSN: 0028-3878
CID: 5343992

PML in immunocompromised patient populations : historical context

Gudesblatt, Mark
ORIGINAL:0016173
ISSN: 1075-4598
CID: 5347912

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea

Frank, Samuel; Stamler, David; Kayson, Elise; Claassen, Daniel O; Colcher, Amy; Davis, Charles; Duker, Andrew; Eberly, Shirley; Elmer, Lawrence; Furr-Stimming, Erin; Gudesblatt, Mark; Hunter, Christine; Jankovic, Joseph; Kostyk, Sandra K; Kumar, Rajeev; Loy, Clement; Mallonee, William; Oakes, David; Scott, Burton L; Sung, Victor; Goldstein, Jody; Vaughan, Christina; Testa, Claudia M
Importance:Tetrabenazine is efficacious for chorea control; however, tolerability concerns exist. Deutetrabenazine, a novel molecule that reduces chorea, was well tolerated in a double-blind, placebo-controlled study. Objectives:To evaluate the safety and explore the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chorea associated with Huntington disease (HD). Design, Setting, and Participants:In this ongoing, open-label, single-arm study that started on December 21, 2013, 37 patients at 13 Huntington Study Group sites in the United States and Australia who were taking stable doses of tetrabenazine that provided a therapeutic benefit were switched overnight to deutetrabenazine therapy. After week 1, the deutetrabenazine dose was titrated on a weekly basis for optimal chorea control. Interventions:Deutetrabenazine administration at a dosage thought to provide comparable systemic exposure to the active metabolites of the prior, stable tetrabenazine regimen. Main Outcomes and Measures:Safety measures included adverse events (AEs), clinical laboratory tests, vital signs, electrocardiograms, and validated scales. Changes in the Unified Huntington's Disease Rating Scale total maximal chorea score and total motor score were efficacy end points. Results:Of the 53 patients with HD screened for the study, 37 ambulatory patients with manifest HD (mean [SD] age, 52.4 [11.5] years; 22 [59%] male and 15 [41%] female; 36 white [97.3%]) were enrolled. Deutetrabenazine was generally well tolerated, with low rates of neuropsychiatric AEs. Safety scales did not reveal subclinical toxicity with deutetrabenazine treatment. Rates of dose reduction or suspension attributable to AEs were also low. Chorea control, as measured by the total maximal chorea score, was maintained at week 1 and significantly improved at week 8 (mean [SD] change from baseline, 2.1 [3.2]; P < .001). Conclusions and Relevance:In patients with chorea, overnight conversion to deutetrabenazine therapy provided a favorable safety profile and effectively maintained chorea control.
PMID: 28692723
ISSN: 2168-6157
CID: 5342202

Characterization of Baseline Lymphocytes and Their Influence on Subsequent ALC and Lymphocyte Subset Decline in Patients with Relapsing Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate in a Retrospective, Multicenter, Observational Study (REALIZE) [Meeting Abstract]

Buckle, Guy; Bandari, Daniel; Greenstein, Jeffrey; Gudesblatt, Mark; Khatri, Bhupendra; Kita, Mariko; Repovic, Pavle; Riser, Emily; Weinstock-Guttman, Bianca; Riester, Katherine; Everage, Nicholas; Von Hehn, Christian; Mann, Monica
ISI:000577381504076
ISSN: 0028-3878
CID: 5342782

Multiple Sclerosis: Brain Atrophy and Computerized Cognitive Testing - A Cross-Sectional Pilot Investigation [Meeting Abstract]

Greif, Eric; Wissemann, Karl; Fafard, Lori; Bumstead, Barbara; Buhse, Marijean; Zarif, Myassar; Gudesblatt, Mark
ISI:000577381503120
ISSN: 0028-3878
CID: 5342772

Multiple Sclerosis: Brain Atrophy and Computerized Cognitive Testing - A Longitudinal Investigation of Changes in Disease Impact [Meeting Abstract]

Greif, Eric; Wissemann, Karl; Fafard, Lori; Bumstead, Barbara; Buhse, Marijean; Zarif, Myassar; Gudesblatt, Mark
ISI:000577381503108
ISSN: 0028-3878
CID: 5342762

A Preliminary Investigation into the Relationship between Visual Evoked Potential Latency (VEP-L) and Outcome Parameters from Optical Coherence Tomography (OCT) in Patients With Multiple Sclerosis (PwMS) [Meeting Abstract]

Tabiri, Kojo; Srinivasan, Jared; Wissemann, Karl; Anand, Damanjyot; Fafard, Lori; Bumstead, Barbara; Buhse, Marijean; Zarif, Myassar; Gudesblatt, Mark
ISI:000577381504346
ISSN: 0028-3878
CID: 5342792

A Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment [Meeting Abstract]

Cohen, Jeffrey A.; Gudesblatt, Mark; Hunter, Samuel F.; Thrower, Ben; Brown, Theodore; Souza-Prien, Cindy; Chernoff, David; Patni, Rajiv
ISI:000395388800053
ISSN: 1352-4585
CID: 5343462

An investigation into the cognitive impact on physical disability in the community in people with multiple sclerosis (PwMS) [Meeting Abstract]

Gudesblatt, M.; Hamid, Z.; Calisi, O.; Wissemann, K.; Fafard, L.; Bumstead, B.; Buhse, M.; Zarif, M.; Blitz, K.; Srinivasan, J.; Sullivan, C.; Wilken, J.
ISI:000413730200242
ISSN: 1352-4585
CID: 5343552

An investigation into the relationship between Optical Coherence Tomography (OCT) and cognitive fatigue in people with multiple sclerosis [Meeting Abstract]

Tabiri, K.; Srinivasan, J.; Wissemann, K.; Anand, D.; Fafard, L.; Bumstead, B.; Buhse, M.; Zarif, M.; Sergott, R.; Gudesblatt, M.
ISI:000413730201156
ISSN: 1352-4585
CID: 5343562